Clinical Trial Update: Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 autologous tumor-infiltrating lymphocyte trial (GTE-001) for advanced lung adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• GTE-001

Snippet

Sponsor: Grit Biotechnology | Conditions: Advanced Lung Adenocarcinoma；Adult | Phase 1 | Status: TERMINATED